Frontiers in Oncology · 2020 · 53 citations · 35 references
MedicineOncologyPharmacologyCancer ImmunologyChemotherapyMolecular OncologyCancer ImmunotherapyCheckpoint Inhibitor TherapyGastric CancerImmune Checkpoint InhibitorsImmune Checkpoint RegulationImmune CheckpointsAntitumor Immune ActivationCheckpoint Modulation In CancerExosomal BiomarkersExosome-mediated Immune SuppressionExosomes In CancerImmune Response InductionImmunostimulatory PathwaysPd-l1 Blockade
Although the cytotoxic chemotherapeutic agent 5-fluorouracil (5-FU) is generally considered to directly kill cancer cells and exert immunostimulatory effects in advanced gastric cancer, accumulating evidence indicates that it upregulates the expression of PD-L1, a representative immune checkpoint blockade molecule involved in negative regulation of the immune response. It was reported that exosomes could transfer functional PD-L1 locally and distantly to suppress the antitumor immune response. However, whether 5-FU alters the expression of exosomal PD-L1 and induces immunosuppression in gastric cancer remains unclear. Herein, we found that 5-FU increased gastric cancer-derived exosomal PD-L1. Importantly, compared with baseline levels, circulating exosomal PD-L1 was significantly upregulated in 21 stage Ⅲ-Ⅳ gastric cancer patients after 2, 4 and 6 repeated cycles of fluoropyrimidine treatment (P=0.009, P=0.047 and P=0.023, respectively), accompanied by decreased amounts of IFN-γ, TNF-α, IL-2, IL-6 and GM-CSF (P=0.014, P=0.004, P=0.009, P=0.031 and P=0.014, respectively). Additionally, circulating exosomal PD-L1 was increased more significantly in clinical non-responders compared with responders (P=0.018). Furthermore, exosomal PD-L1 induced apoptosis in Jurkat T cells and inhibited T cells activation in PBMCs, which could be partly reversed by nivolumab. These results suggested that 5-FU-induced upregulation of exosomal PD-L1 causes systemic immunosuppression in advanced gastric cancer following multiple cycles of chemotherapy, especially after 2 cycles.
35
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel et al. · New England Journal of Medicine · 2018 · 6.6K citations · Full text
Medicine, Oncology, Pharmacology +16
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al. · New England Journal of Medicine · 2015 · 6.2K citations · Full text
Medicine, Oncology, Pharmacology +17
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
Luis Paz‐Ares, Alexander Luft, David Vicente et al. · New England Journal of Medicine · 2018 · 3.6K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Reassessment of Exosome Composition
Dennis K. Jeppesen, Aidan M. Fenix, Jeffrey L. Franklin et al. · Cell · 2019 · 2.9K citations · Full text